Drug intelligence / Profile preview

ITOP2

Development stage: Preclinical
Lead developer: Infinitopes
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

ITOP2 is an off-the-shelf, peptide-based cancer vaccine currently in preclinical development by Infinitopes. As part of the company's pipeline of precision immunotherapies, ITOP2 is designed to target specific cancer-associated antigens to stimulate a robust immune response against malignant cells. The specific cancer indication for which ITOP2 is being developed remains undisclosed by the sponsor, referred to as "Undisclosed cancer indication #2" in company materials.

Beyond the preview

Go deeper on ITOP2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ITOP2.

Explore the full profile